Targeting the Colon: Innovative Drug Delivery Systems for Local and Systemic Therapy

In order to treat conditions like inflammatory bowel disease (IBD) while reducing systemic adverse effects, colon-specific drug delivery systems (CDDS) present a viable approach for both local and systemic medication administration. Targeted administration to the colon decreases off-target effects, increases medication absorption, and improves therapeutic efficacy. Effective formulation design is, however, severely hampered by the distinct physiological environment of the colon, which includes a dense microbial population, changing pH, and restricted fluid content. Due to variations in site specificity and drug release kinetics, conventional CDDS techniques, such as prodrugs, pH- and time-dependent systems, and microbially driven mechanisms, have had only patchy success. With an emphasis on cutting-edge methods including pressure-controlled capsules, osmotic-controlled distribution, and the innovative CODESTM (Colon distribution System), this overview demonstrates the development of colon-targeted drug delivery techniques. Among these, CODESTM shows the most promise since it combines microbial activation and pH sensitivity, enabling precise medication release in the luminal milieu of the colon. This dual-trigger method increases medication stability and absorption, permits dose decrease, and improves targeting accuracy. Additionally, the study describes the most suitable in vitro, in vivo, and in silico methodologies for preclinical evaluation and talks about important physiological characteristics that affect formulation performance, such as transit duration, enzyme activity, and colonic microbiota. Overall, there is a great deal of promise for enhancing therapeutic results in colon-targeted treatments through the strategic development of contemporary CDDS technologies, particularly those that take use of the distinctive characteristics of the colonic environment.